Image Credit: Adobe Stock
Thermo Fisher Scientific is continuing to move fast and furious with its COVID-19 detection efforts. The firm is now collaborating with WuXi Diagnostics and Mayo Clinic to develop a new serology test in response to the COVID-19 pandemic.
Plans call for Waltham, MA-based Thermo Fisher to seek FDA Emergency Use Authorization (EUA) and international regulatory authorizations for the OmniPath COVID-19 Total Antibody Elisa test in the coming weeks.
Thermo Fisher said once approved for use, the OmniPath COVID-19 Total Antibody ELISA test will detect Immunoglobulin M (IgM) and Immunoglobulin G (IgG) to help clinicians determine if a patient has been exposed to SARS-CoV-2.
Gianrico Farrugia, MD, CEO and President of Mayo Clinic, said in a release that, "rapidly expanding access to high-quality testing requires bold collaborations across the laboratory industry. This marks a significant milestone in our national testing response to COVID-19 and was made possible by bringing together the commercialization capabilities of Thermo Fisher Scientific, testing development abilities of WuXi Diagnostics, and clinical and laboratory expertise of Mayo Clinic physicians and scientists."
Jason Liu, PhD, CEO of WuXi Diagnostics, said in a release, "We are pleased to join forces with Thermo Fisher and Mayo Clinic in the battle against the pandemic. This global collaboration of R&D, clinical expertise, manufacturing, and commercialization capability will significantly advance serological testing for COVID-19. WuXi Diagnostics offers an open-access platform for innovative diagnostic solutions. By collaborating with our partners, we're dedicated to supporting healthcare professionals and their patients around the world."
The last few months have been a flurry of activity for Thermo Fisher. In early March the company entered into a deal to boost its diagnostic offerings announcing it would acquire Qiagen for about $11.5 billion. Thermo Fisher was rumored to be interested in acquiring in the Venlo, Netherlands-based company in November of 2019.
Ultimately, the deal, set to close in the first half of 2021, would boost Thermo Fisher’s coronavirus detection efforts with Qiagen’s QIAstat-Dx Respiratory Panel 2019-nCoV test kit.